Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Prestige Consumer Healthcare Inc. (PBH) vs Xeris Biopharma Holdings, Inc. (XERS)

Prestige Consumer Healthcare Inc. and Xeris Biopharma Holdings, Inc. are both Drug Manufacturers Specialty & Generic companies. Prestige Consumer Healthcare Inc. is the larger, with a market value of $2.2B against $1.6B — 1.3× the size. Xeris Biopharma Holdings, Inc. has negative trailing earnings, so its P/E is not meaningful; Prestige Consumer Healthcare Inc. trades at 13.0×. Xeris Biopharma Holdings, Inc. grew revenue faster over the last twelve months: 36.3% against −1.36%. Prestige Consumer Healthcare Inc. has the higher net margin (15.6% vs −5.12%) and the lower return on invested capital (4.70% vs 18.9%). Across the 20 metrics below, Prestige Consumer Healthcare Inc. leads on 12 and Xeris Biopharma Holdings, Inc. on 8.

Valuation

Metric PBH XERS Drug Manufacturers Specialty & Generic median
P/E 12.98 n/m 20.14
P/S 2.00 4.69 2.25
P/B 1.15 n/m 1.90
Price to free cash flow 9.40 28.25 16.54
EV/EBITDA 12.82 32.20 12.29
EV/Sales 3.76 5.08 2.56
Earnings yield 7.70% (1.06%) (2.99%)
Free cash flow yield 10.64% 3.54% 0.00%

Profitability

Metric PBH XERS Drug Manufacturers Specialty & Generic median
Gross margin 53.53% 86.58% 53.94%
Operating margin 26.26% 10.91% 0.00%
Net margin 15.57% (5.12%) 0.00%
Free cash flow margin 21.30% 16.60% 0.00%
Return on equity 9.12% 118.22% (0.40%)
Return on assets 4.30% (4.60%) (3.32%)
Return on invested capital 4.70% 18.88% 0.00%

Growth

Metric PBH XERS Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (1.36%) 36.33% 10.01%
EPS growth (last fiscal year) (8.86%) 100.86% —
Revenue growth, 5-year CAGR 2.91% 70.20% 6.74%
Net income growth, 5-year CAGR 2.93% 0.00% 0.00%

Health

Metric PBH XERS Drug Manufacturers Specialty & Generic median
Debt to equity 1.06 (25.95) 0.05
Current ratio 3.23 1.45 2.31
Net debt to EBITDA 2.77 2.67 0.85

Dividend

Metric PBH XERS Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric PBH XERS Drug Manufacturers Specialty & Generic median
Market cap 2.16b 1.63b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack